Second Department of Clinical Radiology, Medical University of Warsaw, Banacha 1a St., 02-097 Warsaw, Poland.
Second Department Obstetrics and Gynecology, Medical University of Warsaw, Karowa 2 St., 00-315 Warsaw, Poland.
Curr Oncol. 2022 Dec 29;30(1):506-517. doi: 10.3390/curroncol30010040.
The aim of this pilot study was to evaluate the value of imaging techniques, including computed tomography (CT) and magnetic resonance imaging (MRI), in the diagnosis of a tumor-bowel fistula as a rare form of epithelial ovarian cancer (EOC) relapse. We also performed an initial assessment of the effectiveness of the treatment of this form of relapse.
The study group consisted of eight patients with suspected platinum-sensitive recurrence in the form of a tumor/bowel fistula. All patients finished their first line of chemotherapy and subsequently showed complete remission for 6 months or more. To qualify patients for further treatment, CT and MRI were performed, which suggested the presence of a fistula between the recurrent tumor and intestine. DESKTOP study criteria were used to qualify patients for secondary cytoreduction. Second-line chemotherapy was given after secondary debulking.
In all patients, fistulas formed between the tumor and large bowel. On CT, the fistulas were indirectly visible. In all cases, the fistula was visible on MR images, which showed hypointensity on the T2 and T1 post-contrast sequences but did not show restricted diffusion on the diffusion-weighted imaging (DWI) sequence. Patients who were qualified for the study underwent secondary debulking with bowel resection. In all eight cases, the fistula between the tumor and surrounding organs was confirmed. During surgery, seven intestinal anastomoses and one colostomy were performed. No residual macroscopic tumor remained in seven cases (resection R0-87.5%). The progression-free survival (PFS) was 8.4-22.6 months (median 13.4). In the group with cytoreduction R0, the median PFS was 15.5 months (12-22).
In patients with suspected EOC recurrence with clinically suspected fistula, CT scan is not sufficient. In CT, the presence of a fistula is suspected based on indirect symptoms. MRI, as a method with much greater tissue resolution, confirms the diagnosis. In addition, MRI can identify the point of the tumor/bowel junction. This is especially true with a large infiltration covering several intestinal parts. Bowel resection with simultaneous anastomosis is a good and safe solution for these patients. However, appropriate qualification for the procedure is necessary, which will allow for surgery without residual macroscopic disease (R0 surgery). Due to the small number of cases, our results cannot be generalized. We treat them as a hypothesis that can be verified in a larger study.
本研究旨在评估影像学技术(包括计算机断层扫描(CT)和磁共振成像(MRI))在诊断肿瘤-肠瘘这一罕见上皮性卵巢癌(EOC)复发形式中的价值。我们还对这种复发形式的治疗效果进行了初步评估。
研究组包括 8 例疑似铂类敏感复发形成肿瘤/肠瘘的患者。所有患者均完成一线化疗,且随后至少 6 个月完全缓解。为了对患者进行进一步治疗,对其进行 CT 和 MRI 检查,提示复发性肿瘤与肠道之间存在瘘管。采用 DESKTOP 研究标准对患者进行二次减瘤术资格评定。在二次减瘤后进行二线化疗。
所有患者的肿瘤与大肠之间均形成瘘管。在 CT 上,瘘管间接可见。在所有情况下,MR 图像上均可见瘘管,T2 和 T1 增强序列上呈低信号,但弥散加权成像(DWI)序列上未见受限扩散。符合研究条件的患者接受了肠切除的二次减瘤术。在所有 8 例患者中,均确认了肿瘤与周围器官之间的瘘管。手术中,有 7 例进行了肠吻合术,1 例进行了结肠造口术。在 7 例(切除 R0-87.5%)中未发现残留的肉眼可见肿瘤。无进展生存期(PFS)为 8.4-22.6 个月(中位 13.4 个月)。在 R0 减瘤组中,中位 PFS 为 15.5 个月(12-22 个月)。
对于疑似 EOC 复发且临床上疑似存在瘘管的患者,CT 扫描不够充分。在 CT 上,瘘管的存在是基于间接症状来推测的。作为一种具有更高组织分辨率的方法,MRI 可以确诊。此外,MRI 可以识别肿瘤/肠交界处的位置。对于覆盖多个肠段的大面积浸润,这一点尤其如此。对于这些患者,同时进行肠切除和吻合术是一种较好且安全的解决方案。然而,为了确保手术无肉眼残留疾病(R0 手术),需要进行适当的资格评定。由于病例数量较少,我们的结果无法推广。我们将其视为可以在更大研究中验证的假设。